ReviewThe British journal of radiology2018
Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
Review in The British journal of radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 59 citations in OpenAlex.
- Single Photon Emission Computed Tomography Tracer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Article
- Extraordinary therapeutic effect of PSMA radioligand therapy in treatment-refractory progressive metastatic prostate cancer with the transketolase inhibitor benfo-oxythiamine as a radiosensitizer-A case report.Frontiers in medicine · 2024Article
- Reduction of the Renal Radioactivity ofJournal of medicinal chemistry · 2023Article
- Case Report: Long-term complete response to PSMA-targeted radioligand therapy and abiraterone in a metastatic prostate cancer patient.Frontiers in oncology · 2023Article
- Stability Estimation of Gallium Complexes of DOTA Derivatives for Radiotheranostic Applications.ACS omega · 2022Article
- Radiolabeled Bombesin Analogs.Cancers · 2021Review
- Preclinical PET Imaging of NTSR-1-Positive Tumors withCancer biotherapy & radiopharmaceuticals · 2021Article
- The Use of Upconversion Nanoparticles in Prostate Cancer Photodynamic Therapy.Life (Basel, Switzerland) · 2021Review
- Imaging for Response Assessment in Cancer Clinical Trials.Seminars in nuclear medicine · 2020Article
- Towards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between chemotherapy, second-generation anti-androgens and PSMA-directed radioligand therapy) early in the disease course?European journal of nuclear medicine and molecular imaging · 2020Article
- Letter to the Editor re: "Semiquantitative Parameters in PSMA-Targeted PET Imaging with [Molecular imaging and biology · 2020Article
- Semiquantitative Parameters in PSMA-Targeted PET Imaging with [Molecular imaging and biology · 2020Article
- Alpha radioimmunotherapy usingTheranostics · 2020Article
- The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research.Pharmaceutics · 2019Review
- A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.The Prostate · 2019Article
- Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?Translational andrology and urology · 2019Article
- PET imaging in patients with brain metastasis-report of the RANO/PET group.Neuro-oncology · 2019Review
- Article
- Value proposition of PSMA-targeted α-particle radioligand therapy in metastatic prostate cancer.European journal of nuclear medicine and molecular imaging · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alterations at the molecular level are a hallmark of cancer. Prostate cancer is associated with the overexpression of prostate-specific membrane antigen (PSMA) in a majority of cases, predominantly in advanced tumors, increasing with the grade or Gleason's score. PSMA can be selectively targeted using radiolabeled PSMA ligands. These small molecules binding the PSMA can be radiolabeled with γ-emitters like
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.